CRNX Stock Overview
A clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Crinetics Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$56.06 |
| 52 Week High | US$62.53 |
| 52 Week Low | US$30.87 |
| Beta | 0.62 |
| 11 Month Change | -3.28% |
| 3 Month Change | 5.53% |
| 1 Year Change | 75.24% |
| 33 Year Change | 129.75% |
| 5 Year Change | 186.61% |
| Change since IPO | 128.72% |
Recent News & Updates
Recent updates
We're Hopeful That Crinetics Pharmaceuticals (NASDAQ:CRNX) Will Use Its Cash Wisely
Oct 02
Crinetics Pharmaceuticals: Stop, Look, And Listen Before Buying This High-Priced Clinical Stage Biotech
Aug 12Most Shareholders Will Probably Agree With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) CEO Compensation
Jun 01Crinetics: Earlier Data Release For CAH Treatment Bodes Well For Upcoming Conference Data
May 23Crinetics: Paltusotine's Phase 3 Triumph Transforms Trajectory (Rating Upgrade)
Feb 29Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans
Nov 28Is Crinetics Pharmaceuticals (NASDAQ:CRNX) In A Good Position To Invest In Growth?
Aug 08Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans
Dec 31Here's Why We're Not Too Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Situation
Sep 14Crinetics Pharmaceuticals GAAP EPS of -$0.81 misses by $0.15, revenue of $0.44M misses by $0.28M
Aug 12We're Not Very Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Rate
Jun 15Crinetics: Late-Stage Acromegaly Disease Studies Will Be Major Inflection Point
Jun 13Shareholder Returns
| CRNX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.4% | 2.5% | 2.2% |
| 1Y | 75.2% | 16.1% | 31.6% |
Return vs Industry: CRNX exceeded the US Biotechs industry which returned 16.2% over the past year.
Return vs Market: CRNX exceeded the US Market which returned 31.7% over the past year.
Price Volatility
| CRNX volatility | |
|---|---|
| CRNX Average Weekly Movement | 5.4% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CRNX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CRNX's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 290 | R. Struthers | www.crinetics.com |
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company’s lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing’s disease.
Crinetics Pharmaceuticals, Inc. Fundamentals Summary
| CRNX fundamental statistics | |
|---|---|
| Market cap | US$5.20b |
| Earnings (TTM) | -US$277.91m |
| Revenue (TTM) | US$1.04m |
5,004x
P/S Ratio-18.7x
P/E RatioIs CRNX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRNX income statement (TTM) | |
|---|---|
| Revenue | US$1.04m |
| Cost of Revenue | US$50.64m |
| Gross Profit | -US$49.60m |
| Other Expenses | US$228.31m |
| Earnings | -US$277.91m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.00 |
| Gross Margin | -4,774.21% |
| Net Profit Margin | -26,747.83% |
| Debt/Equity Ratio | 0% |
How did CRNX perform over the long term?
See historical performance and comparison